The purpose of this review is, therefore, to evaluate NOD receptors as new targets in cancer immunotherapy and to highlight the NOD1 and NOD2 agonists as well as antagonists reported to exhibit anticancer activity. The gene discussed is NOD2; the disease is cancer.